Get the Stockscreener App
0.8445
1.00%
-0.0085
Pre-market:
.84
-0.0045
-0.53%
Jaguar Health Inc Stock (JAGX) Latest News
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference - Huntsville Item
Breakthrough Plant-Based Drug Takes Aim at $38B ADHD & Schizophrenia Markets - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30% - Simply Wall St
Jaguar Health extends loan maturity, issues stock for royalty interest reduction - MSN
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Jaguar Health announces first SBS-IF patient dosed in IIT trial of crofelemer - TipRanks
Rare Disease Breakthrough: First SBS-IF Patient Dosed in Groundbreaking Pediatric Trial - StockTitan
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO - ACCESS Newswire
This Drug Could Fix The Biggest Problem With Ozempic and Wegovy - StockTitan
Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs - ACCESS Newswire
Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants - ACCESS Newswire
Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer" - ACCESS Newswire
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea - ACCESS Newswire
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - ACCESS Newswire
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) - ACCESS Newswire
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges - MSN
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - ACCESS Newswire
Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming - ACCESS Newswire
Jaguar Health Stock Hits 52-Week Low at $0.81 Amid Challenges By Investing.com - Investing.com South Africa
Jaguar Health Begins Crucial Trial for Rare Disease Drug Crofelemer in UAE Medical Center - StockTitan
Jaguar Health stock hits 52-week low at $0.84 amid challenges - Investing.com Australia
Jaguar Health Awards Strategic RSU Grants to Key New Employees in Retention Push - StockTitan
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Hastings Tribune
Botanical and Plant-Derived Drugs Market to Grow by USD 18.66 Billion (2025-2029), Driven by Government Initiatives and AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase - AccessWire
Jaguar Health CEO to Present at Two Major Healthcare Investor Events in January 2025 - StockTitan
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum - Joplin Globe
Magdalena Biosciences to Submit Groundbreaking IND for First-Ever Schizophrenia Cognitive Treatment - StockTitan
Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2024 Earnings Call Transcript - MSN
FDA approves orphan-drug designation for Jaguar Health’s cholera drug, Crofelemer - MSN
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Barchart
Jaguar Health's Magdalena JV Imports 6kg of Coca Leaf for Novel Mental Health Drug Development - StockTitan
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Corsicana Daily Sun
Jaguar Health Launches Phase 2 Trial for Rare Pediatric Disease Treatment with Orphan Drug Status - StockTitan
FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera - Eagle-Tribune
Jaguar Health Secures FDA Orphan Drug Status for Groundbreaking Cholera Treatment - StockTitan
Jaguar Health stock plunges to 52-week low of $0.87 By Investing.com - Investing.com Canada
Jaguar Health stock plunges to 52-week low of $0.87 - Investing.com
FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES - Quantisnow
Jaguar Health Advances 5 Clinical Trials for Rare Disease Drug Crofelemer, Unveils Development Roadmap - StockTitan
Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Yahoo Finance
Jaguar Health's Phase 3 Trial Shows Breakthrough Results for Cancer Therapy Diarrhea Treatment - StockTitan
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS) - Corsicana Daily Sun
Jaguar Health to Present Promising Breast Cancer Treatment Data at Major Symposium - StockTitan
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):